OCT 17, 2018 09:00 AM PDT

A comparative study of turnaround times for common hematopathology panels on the Leica Biosystems BOND‑III and the Roche Tissue Diagnostics BenchMark ULTRA instruments.

SPONSORED BY: Leica Biosystems
Speakers
  • Senior BOND Product Manager (Global), Leica Biosystems
    Biography
      Position Summary: David has global responsibility for the management of the BOND portfolio (both BOND Clinical & BOND RX) as well as the BOND future development roadmap. This includes close liaison between R&D, Global Support and our Selling Units and Distributors. Key responsibilities include, but are not limited to, instrument hardware and software development, portfolio tracking, product positioning and performance, preparing and executing global launches and general sustainment. All of these responsibilities are underpinned by trying to understand what our customers needs are today, and what they will be in the future.

      David is a molecular biologist by training and started his career in molecular biology before transitioning to anatomical pathology. David joined Vision BioSystems (pre Danaher acquisition) in 2003 as a Lab Scientist, working on the R&D and release of both BOND-MAX and Peloris. He then relocated to the UK as a field support scientist for VBS and transitioned into progressively more senior commercial positions, covering both advanced staining instruments and reagents. David returned to Australia to take on his current role in 2014.
    • Global Support Applications Team Lead, Leica Biosystems
      Biography
        Melissa leads the Global Support Applications team in Melbourne and United Kingdom and has responsibility for the support and training requirements on BOND Clinical, BOND RX, PELORIS, Reagents and APiQ. This includes developing Field Support training and Customer facing training, as well as supporting the field in Applications issues and Customer escalations. She is also responsible for rolling out training/information to the field for new product launches and is a conduit between the customer and R&D team for any development and upgrade needs.

        Melissa is a qualified Medical Laboratory Scientist who has worked as a Senior Scientist and Histology Manager in Australian and Overseas' laboratories. She has also worked in remote Australia assisting the setup of, and training for, a histology laboratory. Melissa joined Leica Biosystems in 2012 as a Global Support Scientist and took on the role of Global Support Applications Team Leader in 2016.

      Abstract:
      DATE: October 17, 2018
      TIME: 09:00am PT, 11:00pm CT, 12:00pm ET
       
      Each patient case request can vary in what is required to make a diagnosis by the pathologist.
      Many times, the pathologist must order a series of tests with multiple antibodies and slides
      grouped into what are commonly called panels. Typically, a pathologist needs to review all slides
      from a panel to sign out a report from a patient case. Rapid case reporting is crucial in permitting
      clinicians to quickly provide patients with certainty, and to triage them to the most appropriate
      therapy.

      This study compares the turnaround times of 10 common hematopathology panels for two
      leading immunohistochemistry slide staining systems – the Leica Biosystems BOND‑III and the
      Roche Tissue Diagnostics BenchMark ULTRA.

      Panel turnaround times were measured by the difference between the first slide starting
      processing and the last slide completing processing on each instrument. Slide processing
      times were analyzed for 24 different antibodies across 10 different hematopathology panels
      comprising a total of 88 slides. The instruments were operated at full capacity (up to 30 slides
      per instrument) and the panels spread over three separate runs. The testing was performed in
      triplicate over three days per platform with a total of 264 slide processed on each instrument.
      Ready-to-use antibody protocols were used on each instrument where available.

      The study demonstrated that across all 10 panels, the BOND-III had a mean speed advantage of
      1.43 hours over the BenchMark ULTRA. Overall, BOND-III had an average panel turnaround
      time of 2hr 33m whereas the BenchMark ULTRA had an average panel turnaround time of
      3hr 59m.

      Show Resources
      You May Also Like
      MAY 24, 2018 09:30 AM PDT
      C.E. CREDITS
      MAY 24, 2018 09:30 AM PDT
      DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
      APR 27, 2018 10:00 AM PDT
      C.E. CREDITS
      APR 27, 2018 10:00 AM PDT
      DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
      AUG 15, 2018 08:00 AM PDT
      C.E. CREDITS
      AUG 15, 2018 08:00 AM PDT
      DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
      MAY 22, 2018 08:00 AM PDT
      C.E. CREDITS
      MAY 22, 2018 08:00 AM PDT
      DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
      JUN 26, 2018 06:00 AM PDT
      C.E. CREDITS
      JUN 26, 2018 06:00 AM PDT
      Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
      MAY 02, 2018 08:00 AM PDT
      C.E. CREDITS
      MAY 02, 2018 08:00 AM PDT
      Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
      Loading Comments...